Bladder Cancer Therapeutics and Diagnostics Market Outlook 2031:
The global bladder cancer therapeutics and diagnostics market size was valued at USD 266.10 Billion in 2022 and is projected to reach USD 430.84 Billion by 2031, expanding at a CAGR of 5.5% during the forecast period 2023 - 2031. The growth of the market is attributed to the rising government initiatives to increase the awareness regarding bladder cancer.
Bladder cancer is the uncontrolled proliferation of abnormal cells in the epithelial cells of the urinary bladder lining. These cells evenly spread through the bladder's lining and into the muscular wall. Tumors are malignant tissues that can spread to other surrounding cells and tissues if they are not treated early. Bladder cancer is treated with urothelial carcinoma, squamous cell bladder cancer, and adenocarcinoma.
Several individuals and healthcare organizations have been affected by the coronavirus disease (COVID-19) pandemic caused by the acute respiratory distress syndrome coronavirus-2 (SARS-COV 2). The global economy was negatively impacted, which increased the burden on the healthcare infrastructure, hampering the market growth.
Bladder Cancer Therapeutics and Diagnostics Market Trend, Drivers, Restraints, and Opportunities
- Rising prevalence of tumors, medication developments, and technological advancements are accelerating the growth of bladder cancer therapies market.
- The presence of favorable reimbursement scenario is projected to boost the market expansion.
- Lack of treatment alternatives can hamper the global bladder cancer treatments market.
- High cost of treatment can hinder the market expansion.
- Increasing R&D activities and rising expenditure on healthcare infrastructure are expected to generate growth opportunities in the global bladder cancer therapies market.
Scope of the Bladder Cancer Therapeutics and Diagnostics Market Report
The report on the global bladder cancer therapeutics and diagnostics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Bladder Cancer Therapeutics and Diagnostics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Products (Therapeutics [Chemotherapy, Immunotherapy, and Others] and Diagnostics [Bladder Ultrasound, Cystoscopy, Urinalysis, and Others]) and Cancer Types (Squamous Cell Bladder Cancer, Transitional Cell Bladder Cancer, and Others)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
GlaxoSmithKline PLC; Johnson & Johnson (Janssen Pharmaceutical); Bristol-Myers Squibb Company; AstraZeneca PLC; and F. Hoffmann-La Roche Ltd
|
Bladder Cancer Therapeutics and Diagnostics Market Segment Insights
Cystoscopy segment is expected to grow at a rapid pace
Based on products, the market is divided into therapeutics, and diagnostics. The therapeutics segment is classified as chemotherapy, immunotherapy, and others. The diagnostics segment is further categorized as bladder ultrasound, cystoscopy, urinalysis, and others.
The cystoscopy segment is expected to grow at a rapid pace during the forecast period. Cystoscopy is a procedure that uses a telescope to look inside the bladder and urethra. Furthermore, cystoscope is a type of endoscope that is inserted into the bladder through the urethra and allows direct visual inspection of the urothelium.
Transitional cell bladder cancer segment is projected to expand at a considerable CAGR
On the basis of cancer types, the market is segregated into squamous cell bladder cancer, transitional cell bladder cancer, and others. The transitional cell bladder cancer segment is projected to expand at a considerable CAGR during the forecast period due to increasing prevalence of transitional cell bladder cancer. Moreover, rising number of diagnostic procedures is estimated to drive the segment growth.
North America is anticipated to constitute a key market share
In terms of regions, the global bladder cancer therapeutics and diagnostics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to constitute a key share of the market during the projected period due to expanding R&D activities and well-established healthcare infrastructure in the region.
Moreover, the existence of significant number of biologics and biopharmaceutical businesses is also contributing to the bladder cancer therapies and diagnostics market in North America.
Segments
The global bladder cancer therapeutics and diagnostics market has been segmented on the basis of
Products
- Therapeutics
- Chemotherapy
- Immunotherapy
- Others
- Diagnostics
- Bladder Ultrasound
- Cystoscopy
- Urinalysis
- Others
Cancer Types
- Squamous Cell Bladder Cancer
- Transitional Cell Bladder Cancer,
- Others
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
Competitive Landscape
Key players competing in the global bladder cancer therapeutics and diagnostics market are GlaxoSmithKline PLC; Johnson & Johnson (Janssen Pharmaceutical); Bristol-Myers Squibb Company; AstraZeneca PLC; and F. Hoffmann-La Roche Ltd.
Request For Customization
Enquiry Before Buying
Speak With Analyst
